Full-Time

Vice President

Qara, Crmn

Posted on 10/31/2025

Integer Holdings Corporation

Integer Holdings Corporation

1,001-5,000 employees

Medical device CDMO for cardiac devices

Compensation Overview

$242.3k - $355.3k/yr

+ Stock awards + Cash-based incentive program

Remote in USA

Remote

Category
Biology & Biotech (2)
,
Required Skills
Risk Management
Requirements
  • BS in engineering, technical, or related discipline; MS preferred
  • Minimum 12 years in Quality Assurance in medical device development or manufacturing
  • 5+ years in multi-site leadership
  • Direct experience in cardiac rhythm management, neuromodulation, or other Class III active implantable medical devices strongly preferred
  • Proven ability to lead in a highly regulated, innovation-driven environment where product reliability and patient safety are paramount
  • Deep understanding of product development for active implantable devices, including verification, validation, risk management, and regulatory submissions
  • Strong track record of building quality organizations that enable innovation while maintaining compliance
  • Experience with advanced problem-solving tools (Six Sigma Black Belt, Statistical Process Control, designed experiments, ANOVA) and continuous improvement methodologies
  • Ability to influence cross-functional teams and represent Integer as a strategic partner to major medtech original equipment manufacturers
  • Excellent communication, strategic thinking, and leadership skills with the ability to inspire teams in a mission-critical, patient-focused environment
Responsibilities
  • Lead all quality assurance and regulatory affairs activities for the Cardiac Rhythm Management and Neuromodulation category, ensuring compliance with EN ISO 13485, EU Medical Device Regulation, 21 Code of Federal Regulations Part 820, and other applicable global regulations
  • Shape category strategy as a member of the CRMN leadership team, influence operational facility planning, and align quality initiatives with business growth priorities
  • Serve as the principal quality contact for the world’s top medtech original equipment manufacturers in CRMN, participating in executive business reviews, partnership meetings, and escalation resolution
  • Provide leadership to site quality assurance managers, design assurance teams, supplier quality, and document control to ensure manufacturing of CRMN products meets quality and performance standards
  • Partner with the centralized regulatory affairs team to manage product registrations, regulatory submissions, and post-market surveillance for Integer-owned CRMN devices
  • Drive robust design assurance, risk management, verification, and validation for new CRMN products, ensuring first-to-market launches are also best-in-quality
  • Establish annual quality metric targets for CRMN, partner with Operations and Engineering to execute data-driven improvement plans, and implement lessons learned from product and process changes
  • Build strong relationships with Enterprise quality assurance/regulatory affairs, Operations, Commercial, and Engineering to standardize best practices and advance Integer’s culture of quality
  • Identify, escalate, and resolve any quality issues that could impact patient safety, therapy effectiveness, or regulatory compliance
  • Recruit, mentor, and develop high-performing quality and regulatory leaders in the CRMN space, ensuring succession readiness and technical excellence
Desired Qualifications
  • MS in engineering or related discipline
  • Direct experience in cardiac rhythm management, neuromodulation, or other Class III active implantable medical devices strongly preferred
  • Experience with Six Sigma Black Belt, Statistical Process Control, design of experiments, and ANOVA as part of continuous improvement
  • Experience leading multi-site quality organizations in medical device development or manufacturing is preferred but not strictly required
Integer Holdings Corporation

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Simplify Jobs

Simplify's Take

What believers are saying

  • Board initiated strategic review on April 30, 2026, exploring sale options.
  • Irenic Capital acquired $99M stake in Q4 2025 as top holding.
  • $200M share repurchase authorization signals management confidence in valuation.

What critics are saying

  • Class action lawsuits by Pomerantz and Bleichmar drain cash via settlements by Q4 2026.
  • Three new products cause 3-4% headwind, slashing H2 2026 margins.
  • Irenic activism forces sale at depressed valuation below $93 target in 12 months.

What makes Integer Holdings Corporation unique

  • Integer specializes in contract manufacturing for Cardio & Vascular medical devices.
  • Organic revenue grew 1.3% in Q1 2026 despite flat overall sales.
  • Robust pipeline targets above-market growth by 200 basis points in 2027.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Adoption Assistance

Parental Leave

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 24th, 2026
Integer VP sells $70K in shares as stock drops 28% in a year

Integer Holdings Corporation shares fell 28% following an insider sale disclosure. Tom Thomas, the company's vice president and corporate controller, sold 825 shares of common stock in an open-market transaction on 13 March 2026, according to an SEC Form 4 filing. The transaction was valued at $70,000 at a reported price of $85 per share. The sale represented 15.85% of Thomas's direct holdings at the time. Following the transaction, Thomas holds 4,380 shares worth approximately $364,000. This marks Thomas's third open-market sale since 2018, following previous sales of 884 shares in November and 1,500 shares in April. Integer Holdings manufactures medical devices and components, generating $1.85 billion in trailing twelve-month revenue.

Yahoo Finance
Feb 26th, 2026
Integer Holdings Q4 earnings beat forecasts on strong Cardio & Vascular demand

Integer Holdings, a medical device manufacturer, reported fourth quarter revenue of $472.1 million and adjusted earnings per share of $1.76, both exceeding analyst expectations. The company posted 5% year-on-year revenue growth, driven by strong performance in its Cardio & Vascular segment. CEO Peyman Khales attributed $30 million in operational improvements to higher sales volume, manufacturing efficiencies and expense management. The company guided adjusted earnings per share of $6.54 for 2026, beating analyst estimates by 3.8%. During the earnings call, analysts questioned the narrowing of organic sales guidance, first quarter margin compression and the company's path to above-market growth in 2027. Management emphasised collaborative customer planning and reaffirmed its current strategy despite activist investor involvement.

Intellectia.AI
Feb 23rd, 2026
Irenic Capital takes $99M stake in Integer Holdings as medical device firm posts 8% sales growth

Irenic Capital Management has acquired a $99.11 million stake in Integer Holdings, purchasing 1,263,663 shares in Q4 2026. The position represents 13.7% of Irenic's assets under management, making it the fund's largest disclosed equity holding. Integer Holdings, a medical device company, achieved 8% sales growth in 2025, reaching $1.85 billion in revenue, with adjusted earnings per share rising 21% to $6.40. The company reported fourth-quarter sales of $472 million and net income of $62 million, up 22% year-over-year. Management projects 2026 adjusted earnings per share between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027. Benchmark analyst Robert Wasserman upgraded the stock from hold to buy with a $95 price target.

Yahoo Finance
Feb 23rd, 2026
Integer posts 21% adjusted EPS growth but warns of H1 2026 headwinds from slower product adoption

Integer Holdings reported strong 2025 results with sales up 8% and adjusted earnings per share rising 21% to $6.40, alongside margin expansion and $105 million in free cash flow. The company returned capital through a $50 million share repurchase and announced an additional $50 million accelerated share repurchase programme. However, management warned that three newer products representing approximately 6% of 2025 sales are experiencing slower-than-expected adoption, creating a 3%–4% headwind for 2026. The company expects flat-to-slightly-down sales and a 200–250 basis point hit to first-quarter operating margin, with recovery and margin expansion anticipated in the second half. Integer maintained its 2026 midpoint guidance, with year-end net debt expected at $1.17–1.19 billion and net leverage remaining at 3.0 times adjusted EBITDA.

Yahoo Finance
Feb 19th, 2026
Integer faces 2026 headwinds from delayed product launches despite $200M buyback and robust pipeline

Integer Holdings, a medical device contract manufacturing organisation, reported fourth-quarter sales of $472 million, up 5% year-over-year, with adjusted earnings per share at the high end of its October guidance range. For the full year 2025, sales increased 8% on a reported basis and over 6% organically, whilst adjusted operating income rose 13%. The company issued 2026 guidance expecting reported sales to be down 1% to up 1%, with a 3% to 4% headwind from three new products facing lower-than-expected market adoption. However, Integer's underlying business is expected to grow 4% to 6%, in line with the market. Integer repurchased $50 million of shares in Q4 and announced plans for an additional $50 million accelerated share repurchase programme under its $200 million authorisation.

INACTIVE